Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/177031
Full metadata record
DC FieldValueLanguage
dc.creatorSantos-Pereira, B-
dc.creatorNogueira, R-
dc.creatorTafesse, Y-
dc.creatorCorreia-Silva, A-
dc.creatorLeite-Gomes, E-
dc.creatorSanchez Sanchez, G-
dc.creatorLuppens, X-
dc.creatorYoung, LEA-
dc.creatorCavadas, B-
dc.creatorVasconcelos, C-
dc.creatorOliveira, D-
dc.creatorLé, A-
dc.creatorTorres, J-
dc.creatorCampar, A-
dc.creatorSerodio, JF-
dc.creatorMarinho, A-
dc.creatorAlves, JD-
dc.creatorTorres, T-
dc.creatorDrake, RR-
dc.creatorVermijlen, D-
dc.creatorAlves, I-
dc.creatorPinho, SS-
dc.date.accessioned2026-10-19T15:40:22Z-
dc.date.available2026-10-19T15:40:22Z-
dc.date.issued2026-
dc.identifier.issn2470-9468-
dc.identifier.urihttps://hdl.handle.net/10216/177031-
dc.description.abstractGlycans play fundamental roles in T cell biology; however, the glycome landscape of γδ T cells remains to be unlocked. Despite the growing importance of γδ T cells in host defense, tissue homeostasis, and diseases, the glycosylation mechanisms guiding their activation, commitment, and function remain poorly defined. By performing single-cell RNA sequencing, we revealed that type 3/γδ T17/interleukin-17A (IL-17A)–committed γδ T cells rely on (N-acetylglucosaminyltransferase 1) MGAT1–MGAT5–mediated branched N-glycosylation. We further demonstrated that the absence of branched N-glycans on γδ T cells acts as a peripheral signal, driving an IL-17A–pro-inflammatory phenotype, alongside a shift to a Vγ4+ subset and the imprinting of innate-like properties. This altered glycoform of type 3 γδ T cells was shown to induce severe psoriasis. γδ T cells from patients with autoimmune and inflammatory diseases exhibited a deficiency in branched N-glycans. Glycan supplementation can reprogram γδ T cells toward a less-pathogenic state, highlighting N-glycans as a previously unrecognized immune checkpoint for γδ T cells.pt_PT
dc.description.sponsorshipThis research was supported by the Portuguese Foundation for Science and Technology (FCT) 2023.16654.ICDT (S.S.P) and 2022.00337.CEECIND (I.A.), the 15 European Union (ERC, GlycanSwitch, grant agreement No. 101071386, S.S.P.; GlycanTrigger, grant agreement No. 101093997, S.S.P.). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be 20 held responsible for them. This study was also supported by the “2022 LRA Lupus Innovation Award” (S.S.P.), the grant from the Núcleo de Estudos de Doenças Autoimunes and Portuguese Society of Internal Medicine (NEDAI-SPMI) (S.S.P.). I.A. is supported by the BIAL Foundation and Portuguese Medical Association (Maria de Sousa Award 29/2023) and the European Society for Clinical Investigation (ESCI 25 Exploratory Research Grant 2024). B.S.-P. is supported by FCT - Fundação para a Ciência e Tecnologia, I.P. UI/BD/151550/2021 (doi.org/10.54499/UI/BD/151550/2021) and EFIS-Immunology Letters (IL) short-term fellowship for PhD fellowship and funding. D.V. is supported by the WELBIO investigator program (WELBIO-CR-2022A– 15) and an ARC grant (ULB). G.S.S. (Télévie), Y.T. 30 (FRIA), and X.L. (ASP) are supported by the FNRS. R.R.D. is supported by National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) grant (P30 DK123704). R.N. is supported by the European Research Council ERC GlycanSwitch project (101071386) for the PhD fellowship. E.L-G. is supported by the FCT - Fundação para a Ciência e Tecnologia, I.P. UI/BD/152866/2022 35 for the PhD fellowship.-
dc.language.isoengpt_PT
dc.publisherAmerican Association for the Advancement of Sciencept_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/Concurso de Projetos de IC&DT em Todos os Domínios Científicos 2023/2023.16654.ICDT/PT-
dc.relationinfo:eu-repo/grantAgreement/EC/HE/ 101071386/EU-
dc.relationinfo:eu-repo/grantAgreement/EC/HE/101093997/EU-
dc.relationinfo:eu-repo/grantAgreement/FCT//UI%2FBD%2F151550%2F2021/PT-
dc.relationdoi.org/10.54499/UI/BD/151550/2021-
dc.relationinfo:eu-repo/grantAgreement/FCT//UI%2FBD%2F152866%2F2022/PT-
dc.relation.ispartofseriesScience immunology, vol.11(124):eaec9553pt_PT
dc.rightsopenAccesspt_PT
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.meshAnimals-
dc.subject.meshAutoimmunity / immunology-
dc.subject.meshGlycosylation-
dc.subject.meshHumans-
dc.subject.meshInterleukin-17 / immunology-
dc.subject.meshMice-
dc.subject.meshN-Acetylglucosaminyltransferases / immunology-
dc.subject.meshPolysaccharides / immunology-
dc.subject.meshPolysaccharides/ metabolism-
dc.subject.meshPsoriasis / immunology-
dc.subject.meshReceptors, Antigen, T-Cell, gamma-delta / immunology-
dc.titleGlycome remodeling programs pathogenic γδ T17 cell responses in autoimmunitypt_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Investigação e Inovação em Saúdept_PT
dc.identifier.doi10.1126/sciimmunol.aec9553-
dc.relation.publisherversionhttps://www.science.org/doi/10.1126/sciimmunol.aec9553-
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1126 sciimmunol.aec9553.pdf10.49 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons